RenalGuard (PLC Medical Systems) trial in Contrast Induced Nephropathy

Results from a new clinical trial of RenalGuard from PLC Medical Systems conducted in Italy -- the first to follow longer-term outcomes -- were presented at the annual conference of the American College of Cardiology (ACC.12), March 24 - 27, 2012, Chicago, Illinois. These results showed that RenalGuard is superior to two alternative methods at reducing rates of mortality, in-hospital adverse events, the need for dialysis, major adverse cardiac events (MACE) and Contrast-Induced Nephropathy (CIN) in high-risk patients undergoing cardiac catheterizations using iodinated contrast. RenalGuard, has been developed to help prevent the onset of Contrast-Induced Nephropathy in at-risk patients undergoing certain cardiac and vascular imaging procedures. The Product is CE-marked and is being marketed in Europe and selected countries around the world. A U.S. pivotal trial, which is currently underway, will also evaluate longer-term outcomes.